7 source-based articles maintained by the HealthRX.com Editorial Team.
Showing 7 of 7 clinical reviews.
A complete billing and prior-authorization guide for THR-β agonists (resmetirom/Rezdiffra), written at MD/PharmD level. Covers ICD-10 coding, HCPCS codes, step-therapy requirements, appeal strategies, and PA letter templates for MASH prescribers.
A prescriber-level DDI reference for resmetirom and the THR-β agonist class: mechanisms, interaction severity, monitoring parameters, and dose-adjustment guidance with primary-source citations.
Complete monitoring bundle for thyroid hormone receptor-β agonists (resmetirom): labs, timelines, dose adjustments, safety signals, and prescriber checklist prepared by the HealthRX.com Editorial Team.
A prescriber-level guide to managing adverse events with THR-β agonists, focusing on resmetirom. Covers hepatic, cardiac, and off-target thyroid effects with dose-adjustment protocols, monitoring timelines, and discontinuation thresholds.
Evidence-based class overview of thyroid hormone receptor-β (THR-β) agonists for MASH. Covers resmetirom mechanism, MAESTRO-NASH trial data, prescribing considerations, and safety profile for clinicians.
A prescriber-level guide to THR-β agonist pharmacology, the MAESTRO-NASH trial, resmetirom dosing, and agent selection criteria for MASH and dyslipidemia.
A prescriber-level guide to THR-β agonist titration and tapering, with dosing protocols, monitoring schedules, and safety checkpoints for resmetirom in MASH.